Does diabetes affect paraneoplastic thrombocytosis in colorectal cancer?
colorectal neoplasms
diabetes mellitus
interleukin-6
thrombocytosis
thrombopoietin
type 2
Journal
Open medicine (Warsaw, Poland)
ISSN: 2391-5463
Titre abrégé: Open Med (Wars)
Pays: Poland
ID NLM: 101672167
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
04
2021
revised:
05
11
2021
accepted:
15
11
2021
entrez:
24
1
2022
pubmed:
25
1
2022
medline:
25
1
2022
Statut:
epublish
Résumé
A large variety of factors can affect colorectal cancer (CRC) survival, including type 2 diabetes mellitus (T2DM) and paraneoplastic thrombocytosis. Although several common factors play a role in their development and platelets are damaged in both diseases, the combined relationship of the three conditions was never investigated previously. A prospective, real-life observational cohort study was conducted with the inclusion of 108 CRC patients and 166 voluntary non-CRC subjects. Plasma interleukin-6 and thrombopoietin levels were measured. Study participants were divided into cohorts based on the presence of T2DM. Platelet count ( Although the independent, disease-worsening effect of paraneoplastic thrombocytosis and T2DM is known, the coexistence of the two did not further impair the survival of CRC patients, suggesting that T2DM has no significant effect over paraneoplastic thrombocytosis.
Sections du résumé
BACKGROUND
BACKGROUND
A large variety of factors can affect colorectal cancer (CRC) survival, including type 2 diabetes mellitus (T2DM) and paraneoplastic thrombocytosis. Although several common factors play a role in their development and platelets are damaged in both diseases, the combined relationship of the three conditions was never investigated previously.
METHODS
METHODS
A prospective, real-life observational cohort study was conducted with the inclusion of 108 CRC patients and 166 voluntary non-CRC subjects. Plasma interleukin-6 and thrombopoietin levels were measured.
RESULTS
RESULTS
Study participants were divided into cohorts based on the presence of T2DM. Platelet count (
CONCLUSION
CONCLUSIONS
Although the independent, disease-worsening effect of paraneoplastic thrombocytosis and T2DM is known, the coexistence of the two did not further impair the survival of CRC patients, suggesting that T2DM has no significant effect over paraneoplastic thrombocytosis.
Identifiants
pubmed: 35071777
doi: 10.1515/med-2021-0407
pii: med-2021-0407
pmc: PMC8760180
doi:
Types de publication
Journal Article
Langues
eng
Pagination
160-173Informations de copyright
© 2022 Gyorgy Herczeg et al., published by De Gruyter.
Déclaration de conflit d'intérêts
Conflict of interest: The authors declare no conflicts of interest. The funding bodies have no role in the design of the study; collection, analysis, and interpretation of data; or in writing the manuscript.
Références
Oncotarget. 2017 Mar 14;8(11):18456-18485
pubmed: 28060743
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Rev Dis Primers. 2015 Jul 23;1:15019
pubmed: 27189025
Clin Colorectal Cancer. 2021 Jun;20(2):170-176
pubmed: 33281065
N Engl J Med. 2012 Feb 16;366(7):610-8
pubmed: 22335738
Rev Assoc Med Bras (1992). 2020 May;66(5):590-595
pubmed: 32638965
Blood. 2014 Jul 10;124(2):184-7
pubmed: 24868077
Gastroenterology. 2015 Mar;148(3):579-89
pubmed: 25461668
BMJ. 2015 Jan 02;350:g7607
pubmed: 25555821
Front Oncol. 2016 Apr 19;6:96
pubmed: 27148488
Nat Rev Immunol. 2015 Oct;15(10):615-29
pubmed: 26358393
Exp Cell Res. 2013 Aug 15;319(14):2216-29
pubmed: 23751564
Platelets. 2016 Jun;27(4):269-75
pubmed: 27136385
J Clin Invest. 2017 Jun 1;127(6):2133-2147
pubmed: 28504650
Arch Med Res. 2012 May;43(4):305-11
pubmed: 22727694
BMJ. 2017 Jun 15;357:j2497
pubmed: 28620089
Oncotarget. 2017 Aug 4;8(37):62478-62488
pubmed: 28977962
Can J Diabetes. 2021 Mar;45(2):186-197.e2
pubmed: 33039329
Prz Gastroenterol. 2020;15(3):215-219
pubmed: 33005266
PLoS One. 2017 Apr 19;12(4):e0176068
pubmed: 28423026
Ann Oncol. 2012 Aug;23(8):1937-1942
pubmed: 22534771
J Clin Oncol. 2016 Dec 10;34(35):4261-4269
pubmed: 27903154
Int J Colorectal Dis. 2019 Feb;34(2):269-276
pubmed: 30421309
Int J Biol Sci. 2020 Jun 14;16(13):2323-2339
pubmed: 32760201
Thromb Res. 2008;122(1):141-3
pubmed: 18061247
Thromb Haemost. 2015 Nov;114(5):876-82
pubmed: 26245672
Diabetes Care. 2015 Mar;38(3):495-502
pubmed: 25552419
Coron Artery Dis. 2003 Aug;14(5):365-71
pubmed: 12878901
J Clin Invest. 2017 Jun 1;127(6):2040-2043
pubmed: 28504654
Anticancer Res. 2017 Sep;37(9):4717-4726
pubmed: 28870890
Thrombosis. 2011;2011:536062
pubmed: 22084665
Blood. 1999 Sep 15;94(6):1952-60
pubmed: 10477724
World J Gastroenterol. 2015 Jun 7;21(21):6470-8
pubmed: 26074686
J Surg Oncol. 2003 Aug;83(4):222-6
pubmed: 12884234
Jpn J Clin Oncol. 2010 Jun;40(6):580-7
pubmed: 20194250
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
J Diabetes Complications. 2017 Sep;31(9):1376-1383
pubmed: 28711195
Medicine (Baltimore). 2016 Jan;95(2):e2502
pubmed: 26765465
J Clin Med. 2019 Nov 27;8(12):
pubmed: 31783601
J Surg Oncol. 2012 Dec;106(7):887-91
pubmed: 22623286
Diabetes Care. 2020 Sep;43(9):2313-2322
pubmed: 32910779
Int J Colorectal Dis. 2010 Feb;25(2):135-40
pubmed: 19898853
World J Gastrointest Oncol. 2014 Feb 15;6(2):34-40
pubmed: 24567794
Magy Seb. 2013 Dec;66(6):331-7
pubmed: 24333978
Dtsch Med Wochenschr. 2017 Nov;142(23):1732-1743
pubmed: 29145678
Cancers (Basel). 2020 Feb 28;12(3):
pubmed: 32121060
Gastroenterol Res Pract. 2016;2016:9701574
pubmed: 26858756
Semin Immunol. 2014 Feb;26(1):54-74
pubmed: 24552665
Diab Vasc Dis Res. 2010 Oct;7(4):251-9
pubmed: 20921090
Cytokine. 2016 Oct;86:100-109
pubmed: 27498215
J Natl Cancer Inst. 2016 Feb 02;108(6):djv402
pubmed: 26839345
Diabetes Care. 2020 Jan;43(Suppl 1):S111-S134
pubmed: 31862753
CA Cancer J Clin. 2010 Jul-Aug;60(4):207-21
pubmed: 20554718
Int J Surg. 2015 Jun;18:1-6
pubmed: 25843227